Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia

Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma

(2011) Bill G. Richendollar et al.   HUMAN PATHOLOGY

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

(2009) L. Zhang et al.   BLOOD

High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma

(2009) Joaquim Carreras et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

(2008) Luc Xerri et al.   HUMAN PATHOLOGY

Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease?

(2008) Federico Caligaris-Cappio et al.   JOURNAL OF CLINICAL ONCOLOGY